Open Access

Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice

  • Authors:
    • Marian Raghubir
    • Chowdhury Nowshin Rahman
    • Justin Fang
    • Hiroshi Matsui
    • Shahana Sultana Mahajan
  • View Affiliations

  • Published online on: November 28, 2019     https://doi.org/10.3892/or.2019.7420
  • Pages: 169-176
  • Copyright: © Raghubir et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcomas are the most commonly occurring malignant bone cancer in young individuals. The survival rate of patients with metastatic osteosarcoma is low and has been stagnant for over two decades. We previously demonstrated that the glutamate release inhibitor, riluzole inhibits osteosarcoma cell growth. Towards the development of more effective therapy, we investigated the delivery of riluzole in human metastatic osteosarcoma xenografts in mice. We compared the efficacy of riluzole delivery by intraperitoneally injecting either free riluzole or riluzole released via two different shapes of iron oxide nanoparticles (nanocage or nanosphere) of size 15±2.5 nm. We monitored tumor size using Vernier calipers and bioluminescence assay and found a significant reduction in tumor size in the riluzole‑treated groups when injected, either in free form or via nanoparticles, compared to the control groups (PBS, nanosphere or nanocage). Importantly, nanocage‑delivered riluzole was most effective in reducing tumor size in the xenograft nude mice. While riluzole delivery induced apoptosis in tumor tissues in all three groups of riluzole‑treated animals, it was highest in tumors from the nanocage‑delivered riluzole group. Therefore, we conclude that riluzole is an effective drug to reduce tumor size in osteosarcoma and the efficacy of riluzole as a apoptotic and tumor‑reducing drug is enhanced when delivered via nanocage.

Related Articles

Journal Cover

January 2020
Volume 43 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Raghubir, M., Rahman, C.N., Fang, J., Matsui, H., & Mahajan, S.S. (2020). Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice. Oncology Reports, 43, 169-176. https://doi.org/10.3892/or.2019.7420
MLA
Raghubir, M., Rahman, C. N., Fang, J., Matsui, H., Mahajan, S. S."Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice". Oncology Reports 43.1 (2020): 169-176.
Chicago
Raghubir, M., Rahman, C. N., Fang, J., Matsui, H., Mahajan, S. S."Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice". Oncology Reports 43, no. 1 (2020): 169-176. https://doi.org/10.3892/or.2019.7420